BEAAlternative Names: BEA protease inhibitor
Latest Information Update: 23 Apr 2003
At a glance
- Originator Medivir AB
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 29 May 2001 This compound is still in active development
- 02 Dec 1997 New profile
- 02 Dec 1997 Preclinical development for HIV-1 infections in Sweden (Unknown route)